Frustration with high prescription drug prices remains an issue that cuts across party lines. Majorities of Democrats, Republicans, and independents want the government to protect access to high-cost treatments for those with chronic conditions.
Consumers want the next president and Congress to rein in prescription drug prices—and to make high-cost drugs available to those with chronic conditions, according to the most recent Kaiser Health Tracking Poll.
Making expensive drugs affordable to those with diseases like cancer or hepatitis C virus was a priority for three-fourths of the public (74%), and it ranked first among the agenda items for 2017. The general need to control drug prices ranked second (63%).
Consistent with earlier polls, the public’s frustration with drug costs cuts across party lines; majorities of Democrats, Republicans, and independents support government action to ensure access to drugs for the chronically ill. A majority of Democrats (75%) and independents (64%) also generally support government price controls on drugs, and nearly half (49%) of Republicans do, as well.
A divided electorate will vote in less than 2 weeks for Democrat Hillary Clinton or Republican Donald Trump, and the future of the Affordable Care Act (ACA) depends on the outcome. Clinton seeks to make adjustments to the ACA to fix what’s not working, while Trump wants to scrap the law, although his path for replacing it is not clear.
While the ACA has received more attention in recent days, overall it is not top of mind as voters head to the polls. For starters, healthcare generally ranks way behind others factors that will drive voting decisions. Democrats are more motivated by the qualities of the candidates, the economy and jobs, foreign policy, and social issues; Republican and independents are more motivated by the economy and jobs, the candidates’ qualities, foreign policy, and immigration.
However, it’s worth noting that the poll was taken October 12-18, 2016, before the news from HHS that the average premium increase for a benchmark silver plan would increase 25% on the exchanges. While only a little more than 10 million people obtain coverage this way, the news has attracted considerable attention in the waning days of the campaign.
After drug costs, top healthcare priorities for voters are making sure health plans have adequate hospital and physician networks (57%), and protecting consumers for surprise medical bills when they visit an in-network hospital, but see an out-of-network doctor (54%).
In general, Democratic and independent voters are more sensitive to the consumer-driven priorities in the poll. Among Republicans, 60% will want to repeal the ACA; only 37% support this overall.
The poll found the public is deeply divided on how to proceed on healthcare. Among Trump voters, 73% want to repeal it and 12% want to scale it back; among Clinton voters, 48% want to expand it and 29% want to leave it intact.
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More